Proficio Capital Partners LLC Purchases Shares of 26,995 Insmed Incorporated (NASDAQ:INSM)

Proficio Capital Partners LLC acquired a new position in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 26,995 shares of the biopharmaceutical company's stock, valued at approximately $1,864,000.

A number of other institutional investors have also added to or reduced their stakes in the business. V Square Quantitative Management LLC increased its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in shares of Insmed in the fourth quarter valued at about $47,000. Venturi Wealth Management LLC acquired a new position in Insmed in the 4th quarter worth approximately $86,000. Quantbot Technologies LP purchased a new position in Insmed during the 3rd quarter worth approximately $133,000. Finally, Avior Wealth Management LLC acquired a new stake in Insmed during the 4th quarter valued at approximately $157,000.

Insider Activity at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at approximately $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the transaction, the insider now owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is currently owned by insiders.

Remove Ads

Insmed Price Performance

Shares of NASDAQ:INSM traded down $1.82 during trading on Monday, reaching $73.07. The stock had a trading volume of 1,994,671 shares, compared to its average volume of 1,981,408. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business has a fifty day moving average price of $75.66 and a 200-day moving average price of $73.79. The stock has a market cap of $13.23 billion, a PE ratio of -13.07 and a beta of 1.28.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. On average, equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on INSM. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Guggenheim reissued a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. UBS Group boosted their price target on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.